2 results match your criteria: "26716Hanyang University Hospital for Rheumatic Diseases[Affiliation]"
Korean LupusPRO: Cross-Cultural validation study for systemic lupus erythematosus.
Lupus
October 2022
Department of Rheumatology, 26716Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea.
Objective: To establish the reliability and validity of the Korean version of LupusPRO version 1.7 (v1.7) for systemic lupus erythematosus (SLE) patients.
View Article and Find Full Text PDFSafety and tolerability of bone marrow-derived mesenchymal stem cells in lupus animal models and a phase I clinical trial in humans.
Lupus
September 2022
Department of Rheumatology, 26716Hanyang University Hospital for Rheumatic Diseases, Hanyang University Institute for Rheumatology Research, and Hanyang University Institute of Bioscience and Biotechnology, Seoul, Republic of Korea.
Objective: Several clinical trials aimed at treating various autoimmune diseases, including systemic lupus erythematosus (SLE), by introducing mesenchymal stem cells (MSCs) have been conducted. However, with refractory lupus nephritis (LN), the outcomes of MSC transplantation are not well known, and further validation is required. In particular, data concerning the safety and efficacy of LN treatment using bone marrow-derived MSCs (BM-MSCs) are still lacking.
View Article and Find Full Text PDF